RxDoctor Payments Data

Jeffrey Hassell, MD

Urology · Plano, TXNPI 1184688236

Payments from drug & device makers

$22,731in general payments, 2019–2025

Across 487 payments — averaging $46.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$4K
  • Axonics, Inc.$3K
  • Neotract Inc.$2K
  • Medtronic$2K
  • Teleflex LLC$2K
  • Boston Scientific$1K
  • plus $8K from 42 others

What the payments were for

  • Travel & lodging$5,82426%
  • Food & beverage$16,84074%
  • Education$670%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,731 in reported general payments places this provider in the 80th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$315,533
Medicare patients
546
Services billed
5,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron63$66,019
GemtesaVibegron52$53,563
ElmironPentosan Polysulfate Sodium11$10,682
Testosterone Cypionate88$4,284
Potassium Citrate ErPotassium Citrate20$3,479
Tamsulosin Hcl254$3,175
Estradiol34$1,919
Silodosin22$1,756
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst117$1,549
Finasteride127$1,495
Solifenacin Succinate20$955
Dutasteride32$742
Alfuzosin Hcl ErAlfuzosin Hcl29$572
Ciprofloxacin Hcl62$257
Levofloxacin65$220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$814$66,01963 claims
Sumitomo Pharma America, Inc.Gemtesa$195$53,56352 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 878 urology providers in Texas.

Other urology in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →